Discovery of type II inhibitors of tgfβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2)

Journal of Medicinal Chemistry

Volumn 58, Issue 1, 2015, Pages 183-196

  Tan, Li ^a   Nomanbhoy, Tyzoon ^b   Gurbani, Deepak ^c   Patricelli, Matthew ^b   Hunter, John ^c   Geng, Jiefei ^a   Herhaus, Lina ^d   Zhang, Jianming ^a   Pauls, Eduardo ^d   Ham, Youngjin ^a   Choi, Hwan Geun ^a   Xie, Ting ^a   Deng, Xianming ^a   Buhrlage, Sara J ^a   Sim, Taebo ^e   Cohen, Philip ^d   Sapkota, Gopal ^d   Westover, Kenneth D ^c   Gray, Nathanael S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ACTIVX BIOSCIENCES INC   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e Korea Institute of Science and Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NILOTINIB; PHOSPHOTRANSFERASE INHIBITOR; PYRIDINE DERIVATIVE; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA; GERMINAL CENTER KINASES; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MOLECULAR LIBRARY; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEOME;

ANIMAL CELL; ARTICLE; BIOLOGICAL FUNCTIONS; CONFORMATION; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; CELL CULTURE; CELL LINE; CELL SURVIVAL; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; PHARMACOKINETICS; PHARMACOLOGY; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; WESTERN BLOTTING;

ANIMALS; AREA UNDER CURVE; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MALE; MAP KINASE KINASE KINASES; MICE; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PROTEOME; PYRIDINES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84920827062     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500480k     Document Type: Article

References (32)

1. OHare, T.; Shakespeare, W. C.; Zhu, X.; Eide, C. A.; Rivera, V. M.; Wang, F.; Adrian, L. T.; Zhou, T.; Huang, W. S.; Xu, Q.; Metcalf, C. A., 3rd; Tyner, J. W.; Loriaux, M. M.; Corbin, A. S.; Wardwell, S.; Ning, Y.; Keats, J. A.; Wang, Y.; Sundaramoorthi, R.; Thomas, M.; Zhou, D.; Snodgrass, J.; Commodore, L.; Sawyer, T. K.; Dalgarno, D. C.; Deininger, M. W.; Druker, B. J.; Clackson, T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Cancer Cell 2009, 16, 401-412
2. Gajiwala, K. S.; Wu, J. C.; Christensen, J.; Deshmukh, G. D.; Diehl, W.; DiNitto, J. P.; English, J. M.; Greig, M. J.; He, Y. A.; Jacques, S. L.; Lunney, E. A.; McTigue, M.; Molina, D.; Quenzer, T.; Wells, P. A.; Yu, X.; Zhang, Y.; Zou, A.; Emmett, M. R.; Marshall, A. G.; Zhang, H. M.; Demetri, G. D. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 1542-1547
3. Gould, A. E.; Adams, R.; Adhikari, S.; Aertgeerts, K.; Afroze, R.; Blackburn, C.; Calderwood, E. F.; Chau, R.; Chouitar, J.; Duffey, M. O.; England, D. B.; Farrer, C.; Forsyth, N.; Garcia, K.; Gaulin, J.; Greenspan, P. D.; Guo, R.; Harrison, S. J.; Huang, S. C.; Iartchouk, N.; Janowick, D.; Kim, M. S.; Kulkarni, B.; Langston, S. P.; Liu, J. X.; Ma, L. T.; Menon, S.; Mizutani, H.; Paske, E.; Renou, C. C.; Rezaei, M.; Rowland, R. S.; Sintchak, M. D.; Smith, M. D.; Stroud, S. G.; Tregay, M.; Tian, Y.; Veiby, O. P.; Vos, T. J.; Vyskocil, S.; Williams, J.; Xu, T.; Yang, J. J.; Yano, J.; Zeng, H.; Zhang, D. M.; Zhang, Q.; Galvin, K. M. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors J. Med. Chem. 2011, 54, 1836-1846
4. Simard, J. R.; Getlik, M.; Grutter, C.; Pawar, V.; Wulfert, S.; Rabiller, M.; Rauh, D. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors J. Am. Chem. Soc. 2009, 131, 13286-13296
5. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2006, 2, 358-364
6. Miduturu, C. V.; Deng, X.; Kwiatkowski, N.; Yang, W.; Brault, L.; Filippakopoulos, P.; Chung, E.; Yang, Q.; Schwaller, J.; Knapp, S.; King, R. W.; Lee, J. D.; Herrgard, S.; Zarrinkar, P.; Gray, N. S. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors Chem. Biol. 2011, 18, 868-879
7. Goldstein, D. M.; Gray, N. S.; Zarrinkar, P. P. High-throughput kinase profiling as a platform for drug discovery Nat. Rev. Drug Discovery 2008, 7, 391-397
8. Pauls, E.; Shpiro, N.; Peggie, M.; Young, E. R.; Sorcek, R. J.; Tan, L.; Choi, H. G.; Cohen, P. Essential role for IKKbeta in production of type 1 interferons by plasmacytoid dendritic cells J. Biol. Chem. 2012, 287, 19216-19228
9. Dzamko, N.; Inesta-Vaquera, F.; Zhang, J.; Xie, C.; Cai, H.; Arthur, S.; Tan, L.; Choi, H.; Gray, N.; Cohen, P.; Pedrioli, P.; Clark, K.; Alessi, D. R. The IkappaB kinase family phosphorylates the Parkinsons disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling PLoS One 2012, 7, e39132
10. Sakurai, H. Targeting of TAK1 in inflammatory disorders and cancer Trends Pharmacol. Sci. 2012, 33, 522-530
11. Dai, L.; Aye Thu, C.; Liu, X. Y.; Xi, J.; Cheung, P. C. TAK1, more than just innate immunity IUBMB Life 2012, 64, 825-834
12. Buglio, D.; Palakurthi, S.; Byth, K.; Vega, F.; Toader, D.; Saeh, J.; Neelapu, S. S.; Younes, A. Essential role of TAK1 in regulating mantle cell lymphoma survival Blood 2012, 120, 347-355
13. Hornberger, K. R.; Chen, X.; Crew, A. P.; Kleinberg, A.; Ma, L.; Mulvihill, M. J.; Wang, J.; Wilde, V. L.; Albertella, M.; Bittner, M.; Cooke, A.; Kadhim, S.; Kahler, J.; Maresca, P.; May, E.; Meyn, P.; Romashko, D.; Tokar, B.; Turton, R. Discovery of 7-aminofuro[2,3- c ]pyridine inhibitors of TAK1: optimization of kinase selectivity and pharmacokinetics Bioorg. Med. Chem. Lett. 2013, 23, 4511-4516
14. Hornberger, K. R.; Berger, D. M.; Crew, A. P.; Dong, H.; Kleinberg, A.; Li, A. H.; Medeiros, M. R.; Mulvihill, M. J.; Siu, K.; Tarrant, J.; Wang, J.; Weng, F.; Wilde, V. L.; Albertella, M.; Bittner, M.; Cooke, A.; Gray, M. J.; Maresca, P.; May, E.; Meyn, P.; Peick, W., Jr.; Romashko, D.; Tanowitz, M.; Tokar, B. Discovery and optimization of 7-aminofuro[2,3- c ]pyridine inhibitors of TAK1 Bioorg. Med. Chem. Lett. 2013, 23, 4517-4522
15. Kilty, I.; Green, M. P.; Bell, A. S.; Brown, D. G.; Dodd, P. G.; Hewson, C.; Hughes, S. J.; Phillips, C.; Ryckmans, T.; Smith, R. T.; van Hoorn, W. P.; Cohen, P.; Jones, L. H. TAK 1 Inhibition in the DFG-out conformation Chem. Biol. Drug Des. 2013, 82, 500-505
16. Ivanov, V. N.; Kehrl, J. H.; Ronai, Z. Role of TRAF2/GCK in melanoma sensitivity to UV-induced apoptosis Oncogene 2000, 19, 933-942
17. Zhang, T.; Inesta-Vaquera, F.; Niepel, M.; Zhang, J.; Ficarro, S. B.; Machleidt, T.; Xie, T.; Marto, J. A.; Kim, N.; Sim, T.; Laughlin, J. D.; Park, H.; LoGrasso, P. V.; Patricelli, M.; Nomanbhoy, T. K.; Sorger, P. K.; Alessi, D. R.; Gray, N. S. Discovery of potent and selective covalent inhibitors of JNK Chem. Biol. 2012, 19, 140-154
18. Sapkota, G. P. The TGFbeta-induced phosphorylation and activation of p38 mitogen-activated protein kinase is mediated by MAP3K4 and MAP3K10 but not TAK1 Open Biol. 2013, 3, 130067
19. Patricelli, M. P.; Szardenings, A. K.; Liyanage, M.; Nomanbhoy, T. K.; Wu, M.; Weissig, H.; Aban, A.; Chun, D.; Tanner, S.; Kozarich, J. W. Functional interrogation of the kinome using nucleotide acyl phosphates Biochemistry 2007, 46, 350-358
20. Patricelli, M. P.; Nomanbhoy, T. K.; Wu, J.; Brown, H.; Zhou, D.; Zhang, J.; Jagannathan, S.; Aban, A.; Okerberg, E.; Herring, C.; Nordin, B.; Weissig, H.; Yang, Q.; Lee, J. D.; Gray, N. S.; Kozarich, J. W. In situ kinase profiling reveals functionally relevant properties of native kinases Chem. Biol. 2011, 18, 699-710
21. Lebakken, C. S.; Riddle, S. M.; Singh, U.; Frazee, W. J.; Eliason, H. C.; Gao, Y.; Reichling, L. J.; Marks, B. D.; Vogel, K. W. Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform J. Biomol. Screening 2009, 14, 924-935
22. Ninomiya-Tsuji, J.; Kajino, T.; Ono, K.; Ohtomo, T.; Matsumoto, M.; Shiina, M.; Mihara, M.; Tsuchiya, M.; Matsumoto, K. A resorcylic acid lactone, 5 Z -7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase J. Biol. Chem. 2003, 278, 18485-18490
23. Arana-Argaez, V. E.; Delgado-Rizo, V.; Pizano-Martinez, O. E.; Martinez-Garcia, E. A.; Martin-Marquez, B. T.; Munoz-Gomez, A.; Petri, M. H.; Armendariz-Borunda, J.; Espinosa-Ramirez, G.; Zuniga-Tamayo, D. A.; Herrera-Esparza, R.; Vazquez-Del Mercado, M. Inhibitors of MAPK pathway ERK1/2 or p38 prevent the IL-1{beta}-induced up-regulation of SRP72 autoantigen in Jurkat cells J. Biol. Chem. 2010, 285, 32824-32833
24. Pereira, L.; Igea, A.; Canovas, B.; Dolado, I.; Nebreda, A. R. Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK EMBO Mol. Med. 2013, 5, 1759-1774
25. Sato, S.; Sanjo, H.; Takeda, K.; Ninomiya-Tsuji, J.; Yamamoto, M.; Kawai, T.; Matsumoto, K.; Takeuchi, O.; Akira, S. Essential function for the kinase TAK1 in innate and adaptive immune responses Nat. Immunol 2005, 6, 1087-1095
26. Schirmer, A.; Kennedy, J.; Murli, S.; Reid, R.; Santi, D. V. Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 4234-4239
27. Brown, K.; Vial, S. C.; Dedi, N.; Long, J. M.; Dunster, N. J.; Cheetham, G. M. Structural basis for the interaction of TAK1 kinase with its activating protein TAB1 J. Mol. Biol. 2005, 354, 1013-1020
28. Wu, J.; Powell, F.; Larsen, N. A.; Lai, Z.; Byth, K. F.; Read, J.; Gu, R. F.; Roth, M.; Toader, D.; Saeh, J. C.; Chen, H. Mechanism and in vitro pharmacology of TAK1 inhibition by (5 Z)-7-Oxozeaenol ACS Chem. Biol. 2013, 8, 643-650
29. Minor, W.; Cymborowski, M.; Otwinowski, Z.; Chruszcz, M. HKL-3000: the integration of data reduction and structure solution-from diffraction images to an initial model in minutes Acta Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62, 859-866
30. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763
31. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132
32. Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L. W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 213-221